Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs

doi:10.3748/wjg.v10.i13.1902

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 13

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3329)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

395

HTML

2548

Figures (1-1)

198

Tables (1-4)

188

Sum=3329

Jul 1, 2004 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Jul 1, 2004; 10(13): 1902-1906
Published online Jul 1, 2004. doi: 10.3748/wjg.v10.i13.1902

Table 1 Lymphocytes proliferation assay (mean ± SD, n = 27)

	³*H-TdR counts (cpm)*
	Peptide1	Peptide2	Peptide3^b	Negative controls
PBMCs from healthy donors	4001.6 ± 328.3	5882.6 ± 397.2	10497.6 ± 859.7	2556.3 ± 211.3
PBMCs from chronic hepatitis patients	3967.5 ± 285.9	4912.3 ± 421.1	7696.2 ± 781.8	2327.6 ± 169.2

^bP < 0.01 vs negative control and peptide1 and 2 groups.

Table 2 Peptide-specific CD₈⁺ T cells induced expressed as ISCs/10⁶ PBMCs (mean ± SD, n = 27)

	ISCs /10⁶ PBMCs
	Peptide1^d	Peptide2^d	Peptide3^d^b	Irrelevant control	Negative controls
PBMCs from healthy donors	1667.5 ± 231.3	4133.7 ± 416.6	9200.5 ± 1638.1	1315.5 ± 321.3	233.3 ± 208.6
PBMCs from chronic hepatitis patients	1420.0 ± 253.5	3915.7 ± 685.9	8966.7 ± 1435.3	1230.0 ± 355.2	245.1 ± 223.3

^bP < 0.01 vs peptide1 and 2 groups,

^dP < 0.01 vs negative control.

Table 3 Percentages of specific targets lysis by HLA-A2⁺ effec-tor CTLs induced by PBMCs from healthy donors with differ-ent peptide antigens (mean ± SD, n = 27)

E/T ratios	Percentage of specific cell lysis (%)
E/T ratios	Peptide1^d	Peptide2^d	Peptide3^d^b	Irrelevant control^a	Negative controls
12.5	22.7 ± 5.3	21.7 ± 6.1	36.1 ± 7.7	3.7 ± 0.7	3.5 ± 0.7
25	29.3 ± 6.5	28.6 ± 6.3	41.4 ± 9.1	5.7 ± 0.7	3.7 ± 0.7
50	33.5 ± 7.1	33.9 ± 8.2	52.3 ± 12.5	7.3 ± 0.9	6.4 ± 0.9
100	37.2 ± 11.2	36.8 ± 10.9	68.4 ± 14.7	7.4 ± 1.1	8.7 ± 1.3

^aP > 0.05 vs negative control,

^bP < 0.01 vs peptide1 and 2 groups,

^dP < 0.01 vs negative control.

Table 4 Percentages of specific targets lysis by HLA-A2⁺ effec-tor CTLs induced by PBMCs from chronic hepatitis B patients with different peptide antigens (mean ± SD, n = 27)

E/T ratios	Percentage of specific cell lysis (%)
E/T ratios	Peptide1^d	Peptide2^d	Peptide3^d^b	Irrelevant control^a	Negative controls
12.5	18.7 ± 3.6	23.1 ± 4.9	30.2 ± 6.1	5.1 ± 0.8	4.3 ± 0.6
25	22.7 ± 4.1	28.6 ± 5.6	38.4 ± 7.4	4.5 ± 0.7	7.1 ± 1.0
50	31.3 ± 6.0	33.9 ± 6.5	52.7 ± 10.3	7.3 ± 1.1	7.7 ± 1.3
100	35.5 ± 5.7	39.1 ± 7.3	58.5 ± 15.9	9.5 ± 1.7	8.5 ± 1.5

^aP > 0.05 vs negative control,

^bP < 0.01 vs peptide1 and 2 groups,

^dP < 0.01 vs negative control.

Citation: Shi TD, Wu YZ, Jia ZC, Zou LY, Zhou W. Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD₈⁺ CTL-mediated cytotoxicity in HLA-A2⁺ human PBMCs. World J Gastroenterol 2004; 10(13): 1902-1906
URL: https://www.wjgnet.com/1007-9327/full/v10/i13/1902.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i13.1902